Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Earnings per Common Share

Earnings per Common Share

9 Months Ended

Sep. 30, 2026

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is calculated using the more dilutive of the treasury stock method or the two-class method. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised and is computed after giving consideration to the weighted average dilutive effect of the Company’s stock options and nonvested restricted stock, where applicable. Anti-dilutive securities are disregarded in earnings per share calculations. For the periods in which the Company reports a net loss, all potentially dilutive securities are excluded from the computation of diluted loss per share as their inclusion would be anti-dilutive.

A reconciliation of net income (loss) and common share amounts used in the computation of basic and diluted income (loss) per common share is presented below.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025











Numerator:
Net loss from continuing operations	$	(7,615)	$	(9,657)	$	(15,729)	$	(14,678)
Net income (loss) from discontinued operations	—		67,073		(248)		64,858
Net income (loss)	$	(7,615)	$	57,416	$	(15,977)	$	50,180









Denominator:
Total weighted-average common shares outstanding	88,274,370		82,454,657		86,614,558		81,223,912






Basic and diluted earnings (loss) per share
Continuing operations	$	(0.09)	$	(0.12)	$	(0.18)	$	(0.18)
Discontinued operations	—		0.81		—		0.80
Total basic and diluted earnings (loss) per share	$	(0.09)	$	0.70	$	(0.18)	$	0.62

The following table represents common stock equivalents that were excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2026 and 2025 because the effect of their inclusion would be anti-dilutive.


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025


Warrants to purchase shares of common stock (1)	—	14,166,644	—	14,166,644
Options to purchase shares of common stock	2,570,248	3,125,177	2,570,248	3,125,177
Outstanding shares in escrow (2)	—	1,717,303	—	1,717,303
Restricted shares of common stock	11,124,172	10,387,606	11,124,172	10,387,606
Total potentially dilutive securities	13,694,420	29,396,730	13,694,420	29,396,730

(1) The warrants expired in accordance with their original terms on May 7, 2026. For the three and nine months ended September 30, 2025, warrants are excluded because the effect of their inclusion would be anti-dilutive as their exercise price exceeds the average market price of the Company’s common stock.

(2) 1,717,303 shares were held in escrow at closing under the Keystone Purchase Agreement. During the nine months ended September 30, 2026, 1,062,294 of these shares were forfeited to the Company, and the remaining 655,009 shares were released to the sellers (subject to a multi-year lockup). Of the forfeited shares, 386,960 remain issued pending cancellation by the transfer agent and are excluded from the weighted-average shares outstanding.